large-cap better posit small cap
under-perform broad market nasdaq index nbi vs
under-perform driven confluenc
overarch concern drug price lower risk appetit due macroeconom
concern trade war china rise interest rate bofaml strategi team see
higher volatil broad market expect high-qual cash-rich
large-cap stock outperform given healthcar sector attract valuat
high qualiti believ large-cap biotech better posit small cap
among top qualiti large-cap
perform qualiti screen cover compani base five equally-
weight metric financi leverag geometr growth rate financi
leverag oper margin return equiti return asset among
large-cap name score highest driven lo financi leverag
strong earn ratio
use valuat tool late econom cycl
late cycl econom growth free cash flow repres valuabl
tool compani valuat within coverag large-cap stock higher long-term
cash yield mean pharma peer mean among large-cap biotech
stock score highest cash dividend yield
 product favor cash burn factor
among cash burn factor strategi team believ one
favor given potenti produc long-term growth calcul
product large-cap biotech stock use ratio estim revenu
current spend celg score fairli close one
anoth return factor slightli lag
significantli fell behind
rais neutral/downgrad nlnk under-perform
upgrad under-perform neutral selinexor encourag
efficaci well expect fda approv penta-refectori myeloma off-set
safeti concern hand downgrad nlnk neutral
under-perform lack convict indoximod underwhelm epacadostat
efficaci phase studi
top-pick
top-pick confid strong launch
dupix atop dermat well recent approv indic
asthma potenti competit risk medicar part reform
alreadi price pipelin upsid libtayo lung cancer bispecif
antibodi underappreci think bmrn core busi track
updat gene therapi valrox repres signific catalyst stock
besid phase result vosoritid achondroplasia
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
dismal biotech perform
larg cap fare better small cap within biotech
fda approv hit anoth histor high drug approv ahead pdufa
large-cap biotech better posit
healthcar valuat attract large-cap cash engin
qualiti style consid
qualiti time buy
qualiti look within healthcar
biotech stock rank term qualiti
large-cap rank highest qualiti screen
small-cap wider qualiti spread
addit fundament consid judg qualiti
free cash flow king
free cash flow yield highest past decad
free cash flow yield continu robust
cash end vs cash
cash end compar
celg cash end steep declin end
cash end compar dec
king princ
 expens expect fairli stabl
expect best product
rel scarciti catalyst
potenti interim analysi aducanumab alzheim diseas
ultomiri ahu next step alxn life-cycl manag
bmn valrox data key determin develop timelin
phase vosoritid data key bmrn grow top-line
blue/celg karmma trial result durabl remain key
phase regener data could make break
gild- see risk phase trial selonsertib monotherapi nash
gild- finch result filgotinib ra expect
vrtx tripl combin readout
ymab omburtamab naxitamab pivot readout
on-going potenti drug launch
could first fda approv therapi peanut allergi
ultomiri launch could assuag concern soliri competit
amgn-aimovig launch gate
soliri gmg nmosd could bolster alxn averag growth
bmrn on-going palynziq launch key life-cycle manag kuvan
blue-lentiglobin approv launch expect eu
celg luspatercept impress two phase trial
inci pemigatinib data like suffici approv
kpti selinexor penta-refractori mm
regn-dupxi rapid grow opportun
regn-libtayo launch cscc earli day
vrtx-symdeko continu drive cf growth tripl combo around corner
catalyst within coverag
top pick
expect strong perform dupix
focu higher dose lead respons
question manag
focu efficaci signal combin
question manag
focu
catalyst manag
focu
catalyst manag
focu
catalyst manag
focu
catalyst manag
focu pipelin updat alzheim interim
question manag
focu
catalyst manag
focu file scd strategi
question manag
focu pipelin growth beyond revlimid
question manag
focu matur data wholly-own asset
question manag
focu regulatori plan
question manag
focu regulatori file underway
question manag
focu reflect point
question manag
savolitinib nsclc fruquintinib gastric
question manag
focu first look pku gene therapi
focu
catalyst manag
focu linzess spin-off clinic readout
question manag
focu progress late-stag pipelin asset
question manag
focu launch selinexor
question manag
focu updat phase
question manag
focu
question manag
focu clinic updat indoximod
question manag
focu long term vaccin data
question manag
focu on-going launch nerlynx bc
question manag
focu tymlo patch trial initi
question manag
focu dupix launch focu oncolog
focu phase strategi
question manag
focu eye mp ii gene edit
question manag
focu eye tripl combin
question manag
focu pivot data regulatori file
question manag
dismal biotech perform
stock under-perform broad market nasdaq nolog index
nbi vs year equiti worst
return sinc financi crisi due macroeconom concern trade war china
increas interest rate under-perform biotech larg driven risk-
trade nbi outperform index peak august gain
vs surpris biotech index lost
reflect small/mid cap stock perform wherea nbi market cap weight
tend track perform larg cap stock better
larg cap fare better small cap within biotech
within coverag univers stock post posit return large-
cap stock typic defens averag perform large-cap
better small-cap nine large-cap post posit
return small-cap stock declin averag loss
large-cap small-cap stock respect tabl chart
among large-cap top pick stock
saw posit return respect significantli outperform
nbi amgn out-performance driven better-than-expect
strength core busi larg share buy-back launch aimovig migrain
well progress promis pipelin asset bcma bi-specif antibodi
vrtx success attribut strong launch symdeko impress result
tripl combin underwhelm data competit
small-cap gain
respect lift rise tide nash due posit clinic data
compani includ expect upcom read-out phase
regener trial share benefit novarti acquisit
avx license technolog hand
winner mani initi public offer biotech owe proprietari
technolog promis earli data well-defin market opportun
tabl averag return cover stock vs index
chart stock perform within coverag univers
fda approv hit anoth histor high drug approv ahead pdufa
fda approv novel therapi number approv
improv last year also repres histor high chart
increas number approv could attribut higher product
time lag fda effici drug approv recent
evidenc mani approv ahead pdufa prescript drug user fee act date
tabl interestingli note recent fda label gener broad
view review process fda decis make scienc base
innov driven
chart fda approv all-tim high
tabl fda drug approv ahead pdufa date
large-cap biotech better posit
flatten yield curv indic potenti late-cycl econom growth well
feder reserv interest hike led signific volatil stock market
especi second half accord bofaml strategi team
cash yield pick higher dividend yield
stock exhibit histor yield curv alway synonym
volatil appear strong correl exhibit therefor given
flatten yield curv strategist believ could see higher volatil
stock market high qualiti name like outperform low qualiti
amid potenti increas volatil cash becom front center capital-expenditure
inflat start weigh profit late cycl economi free cash flow
yield becom valuabl tool compani valuat accordingli large-cap stock
gener free cash flow lower capital-expenditure appear attract small-cap
research develop expens cash burn could signal superior
return long-term growth
exhibit yield higher dividend yield
exhibit yield curv invert spread vs vix
healthcar valuat attract large-cap cash engin
given volatil environ ahead see healthcar stock especi large-cap
biotech stock well posit shown exhibit healthcar remain one
least expens defens sector trade lower level histor well
strong fundament includ earn growth substanti lower
posit sinc help gain momentum
conduct analys evalu qualiti free cash flow product
stock coverag
exhibit bofaml qualiti indic perform correl
chg vix
qualiti style consid
qualiti time buy
qualiti move target gener consist sever criteria broadli
defin well-run compani includ qualit factor busi model
market posit corpor govern quantit measur solid
beta sustain dividend high credit rate better also impact
qualiti notabl low beta alon necessarili mean high qualiti fact low
beta stock histor under-perform market suffer uncertain
volatil gener speak fundament within high qualiti stock tend
stabl
recent year qualiti valuat run counter adag investor must pay
safeti less risk inde valuat gap high low
qualiti stock final revers high qualiti stock start trade
premium low qualiti therefor beyond seek high qualiti investor
start look qualiti attract valuat us equiti quantit
strategi team suggest sector qualiti still rel cheap financi
valu tech select industri
high qualiti stock consist outperform past four bear
market safe volatil capit liquid dri
credit tighten continu re-rat high qualiti stock expect
fed pursu quantit tighten also drive upward pressur cost
capit therefor lever cyclic compani like trade discount cash-
rich self-fund compani us equiti quantit strategi team
recommend defens posit go
qualiti look within healthcar
histor defens industri healthcar outperform last six
bear market fundament factor affect qualiti current strong healthcar
earn growth gain momentum ep surpris posit across
board despit leverag industri near all-tim high credit rate solid
near record number compani rate higher nearli current
healthcar one least expens defens sector trade discount
histor averag
biotech stock rank term qualiti
perform screen compani coverag factor affect qualiti
qualiti score consist five equal weight factor financi leverag
year geometr growth rate financi leverag oper margin roe
high qualiti usual bias toward larger compani typic better
capit predict revenu stream possess matur corpor
govern structur expect large-cap biotech better overal screen
small-cap stock score higher esg rate earn qualiti overal
qualiti surprisingli high qualiti compani also greater number approv
late-stag clinic asset potenti relat large-cap bia screen
gener compani coverag lower financi leverag also higher
qualiti high qualiti compani typic best oper margin roe roa
ep surpris correl qualiti score biotech compani screen
large-cap rank highest qualiti screen
large-cap regeneron vertex highest qualiti score
result low financi leverag strong earn ratio low net debt exhibit
large-cap compani deepest armamentarium approv late-stag
drug rank highest qualiti follow celgen gilead
celg rank lower qualiti
lowest qualiti score amongst large-cap notabl also
low oper margin roe roa celgen highest financi leverag
compani coverag net debt advers impact qualiti
score screen surpris see gilead rank lower
qualiti amongst large-cap like driven rel high financi leverag low
exhibit rank qualiti stock market cap within coverag
drug
leverag credit
earn stabil
bofa merril lynch global research screen identifi rank qualiti intend indic metric may use refer purpos measur perform
financi instrument contract otherwis reli upon third parti purpos without prior written consent bofa merril lynch global research screen creat act benchmark
small-cap wider qualiti spread
high qualiti small-cap also found coverag although spread
highest lowest qualiti name wider exhibit highest qualiti small-
cap strong cash posit low financi leverag favor roe roa
factor financi leverag play largest role determin qualiti
small-cap name follow cash balanc financi leverag late-stag
 also posit reflect overal qualiti surpris adjust ep
correl qualiti potenti due major small-cap compani pre-
puma compani lowest qualiti screen also highest financi
leverag financi leverag growth amongst small-cap along poor roe
roa intercept radiu karyopharm close behind metric well
interestingli mani lowest qualiti compani approv therapi
market underscor import capit structur resourc alloc
small-cap even commerci
exhibit rank qualiti within small-cap biotech coverag
leverag credit
earn stabil
revenu sourc
drug
exhibit rank qualiti within small-cap biotech coverag
leverag credit
earn stabil
revenu sourc
drug
bofa merril lynch global research screen identifi rank qualiti intend indic metric may use refer purpos measur perform
financi instrument contract otherwis reli upon third parti purpos without prior written consent bofa merril lynch global research screen creat act benchmark
addit fundament consid judg qualiti
analysi revenu sourc late-stag composit took shot goal
approach pipelin qualiti captur market size late-stag clinic
pipelin probabl approval/market adopt analysi may
fundament contribut compani pipelin qualiti patent life approv
therapi import compon earn stabil biotech compani
also directli includ assess direct reader fundament
analysi financi model coverag compani factor
examin detail
free cash flow king
suggest strategist free cash flow king go note free
cash flow yield way valu compani late cycl factor
capital-expenditure inflat may start weigh profit biotech
compani gener less affect econom cycl
fundament driven clinic catalyst believ worthwhil analyz free
cash flow yield among biotech univers look invest opportun
free cash flow yield highest past decad
believ large-cap biotech compani well posit volatil market
term cash flow yield highest free cash flow yield past
year chart view biotech compani flush cash given
rais signific capit past year accumul robust capit
expect biotech compani like reli less capit rais near-term look
cash investor
free cash flow yield continu robust
large-cap biotech compani median ltm cash yield vs large-
cap pharma compani index tabl celg
highest ltm free cash flow yield
lowest ltm free cash flow yield dividend-
wise highest ltm dividend yield follow
ltm dividend yield large-cap biotech ltm dividend yield compar
large-cap pharma pay regular dividend large-cap biotech pharma
compani median dividend yield compar dividend
tabl large-cap biopharma ltm dividend cash yield
free cash flow gener among large-cap biotech compani remain strong
continu increas next year past year strong cash
gener use share repurchas well product compani
acquisitions/collabor estim seven larg cap compani
celg gener free cash flow
expect increas expect cash flow gradual
increas next year unlik declin past year driven
cash flow decreas due shock repurchas cash dividend
current high cash level investor expect large-cap biotech
compani consumm transact compani comment
receiv recent manag still believ valuat higher side
manag comment would consid deal anoth
correct smid-cap biotech firm
tabl free cash flow larger-cap biotech
cash end vs cash
approxim billion cash end manag
activ return capit investor compani announc increas
dividend increas share repurchas one-tim
stock repurchas januari increas anoth april
also activ sever collabor small licens deal
entera research inflammatori diseas initi fee addit
recent collabor capac larger deal expect
manag may open larger acquisit scale given
improv oper result balanc sheet recent weak biotech note
amgn debt outstand stabl vs end
cash end compar
compani cash cash equival market secur total end
compar note payabl end
decreas cash due cash use share repurchas conting payment
made former sharehold fumapharm payment note
like ceas conting payment fumapharm tecfidera cumul sale
level reach paid fumapharm annual june
close deal develop novel antisens oligonucleotid
drug candid total payment consist up-front payment
purchas stock total recent paid
exercis option enter clinic studi amyotroph later
sclerosi al pipelin expect continu look opportun
make coupl smaller licensing/ collabor agreement ad neurosci
franchis specialti care area august author
celg cash end steep declin end
celg cash vs mainli driven settlement
acceler share repurchas asr board author increas
februari may respect asr commenc
share repurchas celg cash flow oper
expect celg continu use cash addit in-licens equiti
invest well share repurchas celg total debt
cash end compar dec
cash increas dec total
debt decreas cash driven repay note
payabl loan relat kite acquisit cash dividend
stock repurchas gener oper cash flow nine month
end septemb remain leader cash posit estim
peak roughli billion declin next year hcv
sale declin appoint new ceo expect begin
deploy capit balanc sheet larg scale order return growth
meantim like continu signific share repurchas cash
dividend next year
king princ
strategi team prefer compani strong free cash flow one
expens view posit signal superior return long
term growth good sign biotech compani whose busi model
entir reliant compani abil drive innov examin
expens trend larg cap biotech compani coverag
 expens expect fairli stabl
compani histor spent somewher
revenu smaller compani spend larger portion revenu
develop new drug expens gener converg rang
time come year consensu expect expens rate continu smaller
biotech compani like move closer rate big four
chart percentag revenu next four year consensu
expect best product
measur expect product larg cap biotech compani
coverag use ratio estim revenu current spend
analysi return compani highest expect revenu return per
 spent chart celg group fairli close one
anoth return factor slightli lag
significantli fell behind gener trend make sens younger
compani show lower return develop stabl pipelin
revenu flow like big four notabl outlier even younger biotech due
recent major phase failur largest potenti pipelin candid
epacadostat outlier end spectrum like due
healthi averag top-line growth recent trend spend disciplin
top-line growth compet alxn celg would expect show similar
product ratio howev concern patent cliff
largest drug revlimid weigh compani note celg capit up-front
payment partnership cost would higher celg use
account peer metric use note confound factor
 spend
chart revenu project spend ratio
rel scarciti catalyst
dont see mani industry-mov catalyst catalyst within coverag
includ phase result ahu updat hemophilia
icpt regener trial nash gild stellar trial nash sgmo mp ii
gene edit trial vrtx tripl combin trial investor continu
expect interim analysi biib phase trial aducanumab neither
confirm deni compani
drug launch continu see strong perform gild biktarvi regn
dupix vrtx symdeko earli potenti launch alxn ultomiri amgn
aimovig aimt celg luspatercept regn libtayo close
watch investor
potenti interim analysi aducanumab alzheim diseas
mani investor expect interim analysi phase trial aducanumab
alzheim diseas year howev confirm deni analysi
note recent phase alzheim trial incorpor interim analys
see two scenario provid interim updat aducanumab
meet futil aducanumab show overwhelm efficaci scenario
believ stop trial like scenario trial continu
design case provid updat addit roch state
interim read-out track phase alzheim candid crenezumab
could import read-through biib aducanumab expect final
aducanumab phase result avail
ultomiri ahu next step alxn life-cycl manag
ultomiri alxn next gener antibodi longer treatment interv
everi eight week compar everi week soliri ultomiri bla
treatment paroxysm nocturn hemoglobinuria pnh alreadi approv
fda base numer better near superior efficaci soliri
strong data pnh correspond similarli impress data atyp
hemolyt urem syndrom ahu expect data studi
support sbla file eventu approv ahu approv would give
regulatori back need start convert soliri patient treat
alxn flagship indic pnh ahu ultomiri
bmn valrox data key determin develop timelin
current develop bmn valoctocogen roxaparvovec valrox
gene therapi treatment hemophilia alreadi demonstr
impress factor viii fviii activ level improv level within normal
rang well accept safeti toler profil two year
treatment next step show durabl respons expect report
safeti efficaci data valrox base recent guidanc
discuss fda valrox demonstr continu safeti durabl near
normal level fviii could file acceler approv get
decis whether pursu acceler pathway
data valrox
phase vosoritid data key bmrn grow top-line
also develop vosoritid treatment achondroplasia vosoritid
shown encourag phase data includ notabl sustain improv
annual growth veloc agv fda-approv primari endpoint phase
pivot studi month vosoritid also well toler month
treatment one symptomat hypotens inject administ
requir approv also desir show trend
posit effect endpoint proportion phase data vosoritid
expect around year-end
blue/celg karmma trial result durabl remain key
on-going pivot phase studi patient relapsed/refractori
multipl myeloma finish enrol expect report top-lin result
primari outcom karmma studi overal respons rate orr interim
updat phase trial annual meet american societi clinic
oncolog june demonstr orr cr dose
initi dose-escal cohort bcma baselin level median
month shown overal respons rate similar patient high
low bcma express level base phase result believ karmma
trial enrol patient regardless bcma baselin level like show similar
orr durabl respons compar month patient
bcma level celg plan potenti fda approv
given bcma-target therapi current undergo
pivot studi celg/blu sizabl head start versu rival gsk nv
phase regener data could make break
singl import event come form
phase regener interim data readout ocaliva nash nash make
major icpt valuat posit top-line readout indic
ocaliva potenti approv ocaliva demonstr anti-fibrot effect
phase flint studi fail show similar efficaci japanes trial
regener two co-primari endpoint investor eager see
two met met well payer interpret
result value-proposit perspect competit data nash
announc inhibitor selonsertib
liso-cel celgen celg lead chimer antigen receptor t-cell car-t
candid current undergo pivot clinic studi patient diffus larg b-cell
lymphoma dlbcl primari outcom transcend trial treatment-emerg
advers event teae dose-limit toxic dlt overal respons rate orr
interim data present american societi clinic oncolog confer
show low incid grade neurotox grade cytokin releas
syndrom orr compar favor yescarta kymriah
view approv liso-cel would partial valid acquisit cost
juno note market uptak approv car-t therapi tepid
transcend pivot portion fulli enrol top-line data potenti fda
submiss expect overal see liso-cel competit third mover
car-t dlbcl space solid efficaci potenti better safeti profil
manufactur edg prove benefici scale commerci product
gild- see risk phase trial selonsertib monotherapi nash
expect report top-lin result phase stellar program
selonsertib first-in-class small molecul inhibitor apoptosi signal-regul
kinas treatment nonalcohol steatohepat nash stellar trial
fibrosi patient stellar trial fibrosi patient expect read
respect primari endpoint trial
proport patient achiev improv fibrosi without
worsen nash week event-fre surviv ef week
phase trial patient random mg selonsertib
without simtuzumab patient show
stage fibrosi improv
simtuzumab group respect initi efficaci look encourag mani
caveat trial lead concern upcom phase read-out first phase
trial enrol small number patient nash heterogen diseas
inher variabl second simtuzumab intend inact control
trial protocol third cohort includ patient treat without
simtuzumab render comparison difficult interpret lastli earli result
doublet regimen selonsertib inhibitor fxr agonist perplex
factor view repres risk posit outcom selonsertib monotherapi
contrast believ combin trial might higher chanc await gild
updat
gild- finch result filgotinib ra expect
announc result phase trial filgotinib rheumatoid arthriti
ra patient respond biolog disease-modifi anti-rheumat
drug bdmard filgotinib achiev signific placebo-
adjust improv week respect also
show impress placebo-adjust remiss diseas activ
joint score week respect note enrol
challeng patient inadequ respons intoler biolog
particularli impress among challeng
patient group treat prior bdmard one case retina
vein occlus patient age case resolv infect rate
higher filgotinib group opportunist infect
differ hemoglobin platelet level observ
believ posit result bode well patient
respond methotrex methotrexate-nav patient trial
expect report result confid efficaci
encourag safeti result filgotinib shown safeti data
bear watch addit regulatori submiss gate
male safeti result manta studi given fda requir
februari world congress expect updat clinic data mp ii
program like could see longer follow-up first two dose cohort
well third cohort higher dose
key data includ urin gag reduct id enzym level use sensit assay
importantli look forward urin gag level post ert withdraw urin gag
level stabil post ert withdraw convinc
suppos view repres signific catalyst
given showcas vivo zfn-base gene edit platform
note present initi data mp ii septemb studi inborn
error metabol ssiem meet baselin gag level around high end
normal rang cohort patient saw mean reduct total gag
dermatan sulfat heparin sulfat level week vs baselin howev plasma
id activ undetect either baselin week discrep
gag level reduct id activ caus signific volatil stock
vrtx tripl combin readout
current develop tripl combin
phase trial patient homozyg
het/min mutat top-lin result phase trial report
novemb demonstr lung function improv patient
homozyg mutat top symdeko patient
consist phase trial provid anoth piec evid
correl vitro data clinic outcom enrol two phase trial
evalu complet top-lin result expect
believ combin would like demonstr similar
level efficaci plan evalu result two combin
select one pursu regulatori approv potenti submiss fda expect
later wherea submiss outsid us plan late
tripl combin receiv approv see rapid adopt
homozyg hem/min patient estim peak sale us
ymab omburtamab naxitamab pivot readout
omburtamab antibodi conjug radioact iodin develop
pediatr leptomening metastasi lm neuroblastoma nb data
phase single-cent studi strong month median overal surviv
versu month histor studi therapi also well toler overal
csf radiat half-lif hour pivot trial underway determin
compar dosimetri pharmacokinet new treatment site data
anticip see current clinic data encourag highlight
small market opportun lm nb see upsid potenti
naxitamab human non-radioact antibodi target undergo pivot
studi pediatr patient relapsed/refractori high-risk neuroblastoma see
blend overal respons rate decreas infus time phase
studi favor approv therapi includ unituxin pivot
phase trial studi test compar cgmp naxitamab total
patient addit studi center current enrol discuss
fda y-mab believ orr durat respons
suffici acceler approv bla file naxitamab expect
compar efficaci threshold reach
on-going potenti drug launch
could first fda approv therapi peanut allergi
though widespread grow phenomenon peanut allergi larg unmet
medic need experiment treatment exist avail therapi epi-pen
acut reactiv address underli diseas develop
peanut allergi therapi design desensit patient peanut protein thu
protect accident exposur shown impress efficaci clearli
outperform placebo well accept safeti profil competit
pipelin limit closest competitor dbvt recent withdraw
bla fda review market larg enough multipl player
potenti avail therapi could help initi uptak
submit bla decemb given manag confid
prioriti review could see approv earli august signal
product launch launch watch close move realm
ultomiri launch could assuag concern soliri competit
one high profil drug launch alxn launch ultomiri
treatment pnh tradit new drug launch
focus convert patient soliri ultomiri nonetheless key
launch determin compani abil protect soliri
revenu potenti competit one major concern
investor thu rapid convers patient ultomiri assuag fear
amgn-aimovig launch gate
recent im nrx data show aimovig share among migrain
patient start cgrp therapi compar ajovi emgal
howev script may translat actual sale due free drug program
cgrp manufactur physician feedback suggest aimovig like retain first
mover advantag real world efficaci larg mirror phase clinic data
view migrain patient benefit aimovig may want switch
compet cgrp believ market effort partner novarti also provid
advantag aimovig addit great track record secur contract
payer histor project aimovig us sale vs consensu
soliri gmg nmosd could bolster alxn averag growth
convert pnh patient soliri ultomiri compani also look
expand soliri revenu indic includ on-going launch
gener myasthenia gravi gmg accord track best
soliri launch date continu success launch help maintain
averag top-line growth beyond gmg hope launch soliri
neuromyel optica spectrum disord nmosd back half posit phase
data septemb came pleasant surpris expect file sbla
approv soliri nmosd could mean launch nmosd
repres anoth sourc revenu boost top-line growth
bmrn on-going palynziq launch key life-cycle manag kuvan
bmrn palynziq approv may treatment phenylketonuria pku
also market kuvan treatment pku palynziq larg life-cycl
manag strategi kuvan expect see gener
competit howev palynziq also leg kuvan
requir concurr dietari manag properli maintain safe blood phe level
launch palynziq potenti launch vosoritid valrox expect
help drive bmrn expect growth revenu thu palynziq
key bmrn long term strategi initi launch gradual expect given
titrat period expect see sale acceler patient initi
therapi transit mainten dose
blue-lentiglobin approv launch expect eu
octob european medicin agenc ema accept compani market
author applic investig lentiglobin gene therapi
treatment adolesc adult transfusion-depend -thalassemia tdt
genotyp expect lentiglobin approv eu
efficaci data old manufactur process demonstr transfus
independ patient view transform treatment
beta-thalassemia howev see limit updat eu initi given histor
high reimburs hurdl novel therapi includ gene therapi continu
watch blue price strategi negoti country-to-countri basi
celg luspatercept impress two phase trial
defect red blood cell develop caus anemia often occur myelodysplast
syndrom md -thalassemia patient frequent becom transfus depend
present substanti econom social burden celg/xlrn luspatercept
novel treatment anemia demonstr reduct transfus independ
indic pivot phase studi believ medalist met
primari endpoint statist signific reduct transfus burden compar
placebo luspatercept believ trial result reduct
transfus burden week compar baselin transfus
independ week achiev md patient first
week studi medalist trial combin clean safeti believ
luspatercept competit therapi current use follow failur
erythropoiesis-stimul agent esa assum peak penetr
annual cost estim peak sale across indic
multipl sclerosi ms progress neurolog diseas manifest declin
function central nervou system due immun attack nerv fiber ozanimod
oral modul work prevent lymphocyt move
central nervou system attack neuron ozanimod select bind
aim minim side effect associ broad modul
 bradycardia liver toxic celg receiv refus file ozanimod nda
april fda cite addit non-clin bridg studi pk/pd
requir manag affirm track resubmiss
believ phase data demonstr ozanimod efficaci in-lin oral
treatment overal safeti profil support strong differenti label entri
gener gilenya delay nv patent upheld court like
prevent gener competit see peak sale ms
inci pemigatinib data like suffici approv
updat data pemigatinib fgfr inhibitor cholangiocarcinoma bile duct
cancer fail least one previou treatment present european
societi medic oncolog esmo confer patient
transloc interim result demonstr overal respons rate orr
compar previous median progress free surviv mpf increas
median overal surviv month plan submit full
data studi fda approv model potenti market
opportun pemigatinib cholangiocarcinoma approv
kpti selinexor penta-refractori mm
april pdufa prescript drug user fee act action date selinexor
penta-refractori multipl myeloma mm repres first approv
launch asset close watch investor believ drug
approv indic due unmet need note safeti profil
may preclud adopt therefor remain cautiou launch outsid
academ center use treatment patient monitor patient
necessari mitig unwant side effect
regn-dupxi rapid grow opportun
dupix rapid grow opportun dupix atop dermat ad enjoy
strong launch date weekli addit new patient increas
initi dtc campaign dupix expand moder ad
asthma pediatr ad intern market growth acceler benefit treat
comorbid conveni at-hom administr serv signific
differenti biolog asthma treatment
regn-libtayo launch cscc earli day
ahead pdufa prescript drug user fee act date octob fda
approv regn/sanofi libtayo antibodi treatment patient
metastat cutan squamou cell carcinoma cscc local advanc cscc
elig cur surgeri radiat approv base combin
analysi phase trial two expans cohort phase studi
overal respons rate orr demonstr
metastat local advanc patient respect durat respons last
longer month patient conduct two phase
trial keytruda nave patient carskin experienc patient respect
orr report patient carskin trial note
patient trial receiv prior treatment view efficaci
libtayo similar keytruda
libtayo price per cycl slightli lower keytruda
convers physician suggest patient would
elig resect follow radiat candid libtayo physician
experienc much push back reimburs off-label use keytruda
cscc see hurdl libtayo coverag fda approv
treatment model sale libtayo cscc peak sale
us believ commerci opportun cscc may larger expect
indic includ lung cancer add signific peak sale
vrtx-symdeko continu drive cf growth tripl combo around corner
leader field cystic fibrosi cf first compani
success develop market disease-modifi therapi sinc
approv februari symdeko enjoy strong launch support nativ
patient well patient switch orkambi three approv product
kalydeco orkambi symdeko gener revenu repres
growth y-o-i asid momentum approv therapi recent success
tripl combin variou phase phase studi provid significantli
improv benefit patient gate mutat homozyg mutat
heterozyg function mutat heterozyg
function mutat het/min tripl combin expect readout
plan choos one regimen submit fda approv later mid-
year expect expand commerci opportun anoth cf
market project top bottom line compound-annual-growth-rate respect
catalyst within coverag
highlight key catalyst compani within coverag tabl
tabl catalyst within coverag
present expect jp morgan healthcar confer
dose expand dose cohort afp phase studi
earn expand safety/efficaci data patient high
dose cohort studi
mid first look anti-april mm
initi phase sting hn
updat phase sting nv combin
defin path forward ocaliva psc
interim data readout phase regener studi
ocaliva nash
februari approv jakafi agvhd base reach
fda file pemigatinib cholangiocarcinoma
tabl catalyst within coverag
submiss
initi phase studi egg allergi
potenti advisori committe meet
potenti us approv commerci launch
ind submiss alnut allergi
initi phase studi alnut allergi
februari epo hear discuss patent applic
phase top-lin data ultomiri ahu
file soliri approv nmosd
phase data waiha
initi phase studi ultomiri gmg
file manufactur sbla
potenti launch soliri nmosd
cardiovascular outcom data azn hif inhibitor
fda decis resubmiss bla even
district court case decis enbrel patent case ith
updat phase plan alzheim
phase anti-tau psp
phase initi trigemin neuralgia phase
initi await regulatori interact review plsr data
phase al
phase initi ms
potenti interim analysi aducanumab phase trial
top-lin data karmma trial relapsed/refractori
potenti file fda relapsed/refractori mm
initi pivot trial sickl cell diseas
continu updat lentiglobin
trial -thalassemia sickl cell diseas
potenti approv lentiglobin thalassemia
complet enrol phase studi
eu decis file palynziq
ind file bmn freidriech ataxia
three year updat phase studi valrox
decis pursu acceler approv valrox
ind file bmn gene therapi pku
updat phase studi crigler-
updat phase studi
ind file pomp
potenti notif next gene therapi pipelin
capmatinib meki file nv lead mileston
data phase pemigatinib continu dose uc
data phase reach acut gvhd
data phase reach chronic gvhd
data phase itacitinib newli diagnos agvhd
data phase studi topic ruxolitinib vitiligo
data citadel studi fl mzl mcl
baricitinib phase data atop dermat report lilli
approv linzess china ibs-c
complet spin-off new co
phase data hfpef diabet nephropathi
phase result wet-amd/dme/rvo
februari present week phase data angiogenesi
dose start phase global trial wet-amd
ind submiss china
initi phase trial dr/dme us/eu
initi two phase trial wet-amd dme
respect china
eu market applic submiss selinexor penta-refractori
april regulatori decis selinexor penta-refractori mm
regulatori file selinexor diffus larg cell lymphoma
 phase boston result svd vs vd mm
phase seal liposarcoma
preliminari six month data full pediatr cohort top-lin
data adult dose escal studi
preliminari data dose escal phase phase trial
xlrp
earli releas clinic materi cgmp facil
achromatopsia initi phase trial
data adult dose escal cohort six month data
pediatr patient phase trial trial
discuss fda pivot design
potenti pivot trial initi
updat result phase trial indoximod plu radiotherapi
pediatr patient recurr malign brain tumor
updat data phase trial indoximod plu radiotherapi
data phase trial plu paclitaxel
file ebola vaccin bla merck
data person vaccin opdivo
data person vaccin keytruda
cta eu person cellular therapi
ind off-the-shelf vaccin er breast cancer
meet fda potenti strategi neratinib mutant
june/juli file neratinib third line metastat breast
tabl catalyst within coverag
re-fil ozanimod ms
complet enrol phase north uc
file luspatercept md -thalassemia
open accrual liso-cel phase studi r/r
pivot data dlbcl nda file approv
file revlimid plu rituximab r/r nhl
updat result
updat result
phase north moder sever uc
preliminari safety/efficaci
monotherapi dose expans ipilimumab combin cx-
fda file ba monotherapi fdc pill
ema file ba monotherapi fdc pill
biomark data phase attr-cm studi
initi phase attr-cm attr-pn
initi phase attr-cm competitor
launch pfe tafamidi attr-cm alni
onpattro attr-pn
nomin gene edit candid pku
complet build phase gmp
initi initi data report gene
therapi pku
top-lin result stellar trial selonsertinb nash
finch result filgotinib phase
top-lin result stellar trial selonsertinb nash
data atla phase studi selonsertib and/or gs-
and/or patient advanc fibrosi due nash
earli initi savolitinib line nsclc patient post
interim analysi phase frutiga fruquintinib/taxol combo
interim analysi phase studi sulfatinib
enrol patient phase emerald studi
initi tymlo patch abaloparatide-td phase trial
forteo patent expiri anticip entranc teva gener
complet phase atom studi tymlo male
march pdufa dupix adolesc atop dermat patient
april pdufa praluent reduc cardiovascular event
may pdufa eylea diabet retinopathi
resubmit approv eylea pre-fil syring
earli januari corpor updat includ expect
earli updat program wet-amd
earli updat program hofh
updat program mp ii
dose first patient mp
februari updat mp ii program world congress
earli data expect beta-thalassemia
earli data mp
earli data sb-fix hemophilia gene edit program
updat hemophilia gene therapi program
top-lin result phase trial
mid-year submiss one tripl combin fda approv
initi phase trial cf patient gate
potenti updat patient beta-thalassemia
phase studi result dipg
phase studi result dsrct
pivot phase data omburtamab lm nb
fda file omburtamab lm nb
pivot phase data naxitamab r/r nb
fda file naxitamab r/r nb
top pick
expect strong perform dupix
given concern around medicar part reimburs seem contrarian
pick eylea drug paid medicar dollar amount howev believ
risk price share alreadi market share eylea continu
increas face much cheaper off-label avastin high rebat lucenti
roch superior efficaci dose conveni offer eylea dupix
import growth driver indic atop dermat
asthma approv fda project global sale dupix
compar consensu grow y-o-i addit expect
investor focu regn libtayo antibodi potenti lung cancer
bispecif antibodi particularli lymphoma
expect provid updat hemophilia gene therapi valrox
median level factor viii near normal rang
factor viii level close expect ask
fda acceler approv valrox market opportun signific
estim peak sale valrox approv view downsid
manag investor consid valrox high risk clinic program end
expect phase result vosoritid achondroplasia
patient world achondroplasia repres larg commerci opportun see
probabl success vosoritid given posit phase data long-term
updat phase result expect ind file pku gene therapi
believ outperform biotech sector rich clinic
adap share under-perform nasdaq biotechnolog index
share driven expect first-look respons data
wholly-own asset mage clean safeti data program
throughout first half year support stock stock ralli ahead
european societi medic oncolog esmo meet octob mage data
receiv late break design poster discuss howev hope
respons met send stock back data
present tell year futur success complex cell
exhibit adap price perform rel
subject cell genet alter cell receptor tcr better attack
destroy cancer cell person therapi requir patient
requir hla human leukocyt antigen type tumor antigen express
diseas treatment manufactur take week cell
return patient intraven follow lymphodeplet pre-condit regimen
chemotherapi given increas competit adap lead indic
impract administ complex person therapi last-lin
set believ current price accur reflect valu adap lead
candid cash posit updat adap cash
posit reduc probabl approv
decreas po
focu higher dose lead respons
expect look safeti efficaci data wholly-own pipelin
includ engin tcr afp alphafetoprotein
varieti tumor type follow earli efficaci safeti present throughout
demonstr best respons stabl diseas dose
billion spear cell updat data expect includ dose rang
thought necessari attain clinic respons billion cell focu
efficaci safeti enrol studi find patient correct hla
tumor antigen express could remain hurdl
updat data investor confer
dose expand dose cohort afp phase studi
earn expand safety/efficaci data patient high dose
cohort studi
question manag
expect earn call updat clinic studi
adap tcr differenti compet tcr program
nv celg
would expect depth respons complet respons
durabl respons year seen car-t cell
shown cell persist produc cytokin cell
shown anti-tumor efficaci ex vivo
expect data higher dose cohort mage
safeti schema place manag anticip advers event cytokin
current screen failur rate hla/antigen work
improv
long current manufactur time patient get bridg
chemotherapi wait treatment see scalabl beyond
patient per week current manufactur site
express level tumor associ antigen influenc respons mage-
express antigen expect clinic set
patient tumor-associ antigen posit express target
epitop patient screen
peptid share predict epitop similar
ny-eso
comment commerci strategi wake dynam
competit market nsclc see tcr treatment
development strategi mani
indic express higher level
use switch licens blcm asset help
compet car-t bispecif program
expect initi combin studi adap tcr mrk
keytruda indic therapeut compound interest
plan improv function persist tcr approach
differenti factor second gener tcr
would repeat cell infus and/or combin io agent
affect clinic respons expect clinic studi
chang oncolog treatment landscap see largest
unmet medic need potenti adap tcr treatment paradigm
share significantli under-perform
biotechnolog index sinc ipo share volatil focus
present sting data partner nv octob end
research licens pact regard adro double-delet listeria ladd platform
send stock surpris shut wholli own
ladd program decemb neg competitor data
european societi medic oncolog esmo sent share due deflat
hope sting monotherapi activ present adro/nv sting
societi immunotherapi cancer echo neg investor sentiment
remain cautiou stock reduc probabl approv
lower po
exhibit price perform rel
lead posit sting stimul interferon gene b-select
antibodi platform believ program potenti lack near-term
catalyst elicit excit investor sting remain high-risk high-reward
asset believ lack monotherapi activ evolv immuno-oncolog
space could present challeng continu pave way trial could
focu efficaci signal combin
present data phase studi societi
immunolog cancer confer show partial respons patient
clear dose respons observ dose test rang
respons observ dose level sting prove tractabl
target immun stimul believ partner could signific
part valuat howev appear gener well
toler dose concern overal lack efficaci
monotherapi await matur data monotherapi studi well data
combin antibodi spartalizumab antibodi
wholly-own first-in-class anti-april antibodi enter phase studi
multipl myeloma see earli data studi next year critic
bolster sentiment toward adro overal pipelin success adro b-select
program offer potenti upsid current po
mid first look anti-april mm
initi phase sting hn melanoma
updat phase sting nv combin studi
question manag
detail cgas-st lilli partnership direct
see program go plan enter clinic
given pre-clin patient data show lack efficaci improv higher
dose dose level consid take forward subsequ trial
plan enrol addit patient lower dose level given data
think lack monotherapi data think
due patient characterist factor base dispar
follow discontinu ladd program continu develop
pladd program data support decis
manufactur time pladd improv make
program reduc time
indic patient would benefit person approach
anticip matur combin data
plan dose patient viscer lesion safeti efficaci
data led decis enrol patient studi
monetari mileston associ
nv return sting program base agreement would
think sting agonist compar oncolyt virus
distinguish yervoy well bmi next-
indic interest target antibodi
posit competit landscap
anti-april therapi effect post-bcma therapi
asset compar competit bi-specif adc car-t
posit competit mm landscap
strong back competitor phase trial miss
under-perform close year year
month lead phase palisad top-line aimt share price rose strongli
howev despit posit phase data investor sold news like due
dearth meaning catalyst
exhibit price perform rel
aimt clinic focu treatment food relat allergi lead pipelin
asset treatment peanut allergi shown impress phase
efficaci demonstr abil induc maintain peanut desensit
competit dbvt delay see potenti stronger peanut allergi
market posit anticip see potenti launch project peak
sale
focu
first import event come earli form phase
artemi data data dictat aimt file strategi eu
import catalyst howev potenti advisori committe
meet subsequ fda approv advisori committe meet
give us initi impress fda think well give us idea
doctor think approv therapi fda accept
dbvt bla submiss advisori committe may doubl session give us
insight fda doctor think asset beyond peanut allergi
expect initi phase studi treatment egg allergi
treatment walnut allergi respect
submiss
initi phase studi egg allergi
potenti advisori committe meet
potenti us approv commerci launch
ind submiss walnut allergi
initi phase studi walnut allergi
catalyst manag
plan educ non-allergist administ
think key point discuss potenti advisori
dbvt find rout approv see market split
opportun patient outsid older patient
see market term desensit peanut-protein base
drug monoclon antibodi
plan intern partner
preclin data support ind egg walnut allergi
share under-perform versu
stock perform volatil hit high also dip low
out-performance driven posit ultomiri pnh soliri nmosd data
well strong earn beat under-perform came competitor news
flow minor ex-u sale practic issu concern around soliri european patent
exhibit price perform rel
strong revenu soliri paroxysm nocturn hemoglobinuria pnh atyp
hemolytic-urem syndrom ahu continu deliv consist growth
despit enrol impact ultomiri competitor soliri launch gmg
provid addit boost top-line futur perform depend
continu earn beat strong ultomiri ahu data rapid convers soliri
patient ultomiri investor also look continu build
pipelin busi develop activ like recent wilson syntimmun
acquisit collabor dicerna complement pharma
focu
focu continu soliri sale includ on-going launch
soliri gmg howev approv ultomiri februari rapid convers soliri
patient longer-act follow-on also top mind specif look
alxn abil secur contract foreign govern approv soliri
anoth indic nmosd also focu indic
provid anoth sourc growth alxn flagship drug also look updat
alxn pipelin includ ultomiri ahu gmg subcutan ultomiri
waiha wilson diseas
februari epo hear discuss patent applic soliri
februari fda pdufa data ultomiri pnh
phase top-lin data ultomiri ahu potenti file
file soliri approv nmosd
phase data waiha
initi phase studi ultomiri gmg
file manufactur sbla intraven ultomiri
potenti launch soliri nmosd
catalyst manag
frame expect ultomiri ahu
strategi convert patient ultomiri us ex-u
think market soliri nmosd compar
approv indic bolu identifi patient
think strensiq market matter execut
consist patient add
target look complement dicerna
long epo hear expect decis european
see greatest competit threat complement
indic look target beyond pnh ahu mg
share outperform versu notabl
one two large-cap biotech compani end year posit return
out-performance larg driven amgn consist earn beat strong capit
return form dividend share buyback key patent case win later
year benefit promis clinic data bispecif
multipl myeloma strong launch newli approv aimovig migrain despit
concern gener sensipar biosimilar neulasta entri well medicar part
exhibit price perform rel
maintain buy rate given compani strong capit posit
underappreci pipelin compani cash balanc sheet
free cash flow gener grant deal size flexibl abil
consist return capit sharehold pipelin extens
oncolog platform includ numer modal car-t bite small
molecul grow neurosci franchis includ migrain
prevent tezepelumab asthma earli stage cardiovascular asset top-line
growth expect somewhat stagnant next coupl year given
biosimilar gener drug exposur amgn strong balanc sheet
underappreci pipelin help fill hole
focu
import year set top-lin growth expect care
given grow exposur biosimilar neulasta potenti entri gener sensipar
slower expect repatha growth look launch aimovig
parsabiv amgevita potenti mvasi kanjinti eas revenu runoff
beyond updat enbrel patent case sandoz key indic
amgn abil protect largest legaci product cardiovascular data
competitor azn roxadustat anemia lead indic potenti impact
amgn esa franchis epogen aranesp shift stori pipelin
key data readout oncolog neurosci cardiovascular inflamm
pipelin could reassur investor amgn long term strategi outsid
investor look continu capit return and/or transform deal
cardiovascular outcom data azn hif inhibitor roxadustat vs
fda decis resubmiss bla even
district court case decis enbrel patent case sandoz
catalyst manag
prioriti capit alloc given current valuat biotech
give us updat even discuss fda progress
see intern price index affect busi
kind convers rate see patient aimovig free
what statu litig sensipar expect
take intensifi convers parsabiv pre-gener senipar entri
repatha list price adjust indic futur price model
kind impact see biosimilar neulasta entri
onpro protect
bold made initi public offer juli open sinc
bold seen low high june volatil year
bold outperform strong data aav compani gene
therapi program also under-perform line gene therapi compani
recent small-cap sell-off hit bold bring share price near high
concern around pomp gene therapi program also worri
investor drag bold
exhibit bold price perform rel
audent early-stag compani focus develop aav vector gene
therapi orphan diseas addit valid aav gene therapi
mechan compani bold demonstr posit preliminari data
gene therapi xlmtm crigler-najjar provid
proof concept monogen natur diseas bold target along
proven mechan aav gene therapi give us confid bold abil
develop effect therapi target indic addit given fda
focu manufactur gene therapi product bold in-hous cgmp facil put
uniqu posit meet high qualiti standard agenc
focu
bold show addit data clinic studi
specif provid higher dose data longer efficaci durabl
includ long-term data higher dose gener patient
data investor specif look higher dose provid
greater durabl respons trend compani demonstr preclin
model beyond two program focu get greater clariti
gene therapi pomp diseas includ ind file bold next pipelin
updat phase studi crigler-najjar
updat phase studi xlmtm
ind file pomp
potenti notif next gene therapi pipelin candid
catalyst manag
tell us modif expect make pursu ind
differ efficaci durabl expect see higher dose
think lower dose didnt achiev desir level
expect provid clariti plan
plan beyond four program current pursu
kind salesforc anticip need market gene
share slightli outperform nasdaq biotechnolog index
versu nbi biib
share driven primarili stabil multipl sclerosi ms franchis
progress spinraza launch spinal muscular atrophi sma clinic trial result
alzheim pipelin earli share pressur mani thought sma
launch would slow near-term us due patient complic
manag announc closely-watch aducanumab phase trial would
upsiz base blind statist review februari share driven
primarili posit phase result alzheim diseas share
gain new posit data share correct almost
question surround valid data ensu
exhibit price perform rel
ms franchis stabil despit headwind competit price debat
us market manag continu take prudent measur expens
manag focus pipelin diversif believ
import year strengthen base busi expand pipelin slew
expect phase trial read-out investor remain focus progress
alzheim diseas remain highest risk/reward platform univers
focu pipelin updat alzheim interim
pipelin progress diversifi biib portfolio spotlight year
look forward multipl earli stage readout throughout neuroimmunolog
neuromuscular disord movement disord ophthalmolog pipelin ultim
dark hors would interim look phase aducanumab trial alzheim
diseas howev compani comment chanc interim analysi
investor stuck wait final data updat develop plan
also close watch expect set phase roll
submiss phase would repres upsid updat sma competit landscap
biib in-hous gene therapi close watch
updat phase plan alzheim
phase anti-tau psp
phase initi trigemin neuralgia phase initi
await regulatori interact review plsr data
phase initi ms
question manag
expect regard ms stabil throughout believ
major impact ocrevu bake
comment net price ms franchis light polit rhetor
file last year head-to-head toler vs tecfidera result
expect label includ head-to-head data
think long-term trajectori tecfidera
growth driver ms slow spinraza growth
updat comment sma gene therapi question surround preclin
packag fda
think spinraza franchis light competit gene
therapi expect oral therapi
spinraza growth driven captur adult market current
strategi find educ patient
plan follow phase data would initi
think develop strategi alzheim
aducanumab
expect data aducanumab chanc interim
appetit open larger later-stag
expect biosimilar franchis impact
bottom line
one better fare name realm mid/large-cap biotech
outperform nbi vs nbi driven
strong data clinic pipelin program includ propos gene therapi
hemophilia specialist orphan drug develop polit pressur drug
price limit effect oper perspect
met commit doubl digit top-line growth expect level
growth continu acceler come year
exhibit price perform rel
maintain buy rate compani averag growth profil
burgeon pipelin achiev profit bmrn stori
maintain profit continu expand product portfolio
acceler top-line growth orphan drug product vimizim naglazym kuvan provid
solid base revenu growth acceler expect driven
recent approv palynziq potenti product bmn valrox hemophilia
vosoritid achondroplasia
focu
crucial year late stage pipelin report three
year updat valrox follow compani decis whether
pursu acceler approv asset data notabl give us look
longer term durabl valrox also report top-line data
phase clinic asset vosoritid solid data program indic
bmrn abil add anoth potenti product portfolio outsid
two program may also file ind second gene therapi bmn
phenylketonuria
complet enrol phase studi valrox
eu decis file palynziq
ind file bmn freidriech ataxia
three year updat phase studi valrox
decis pursu acceler approv valrox
ind file bmn gene therapi pku
catalyst manag
time pivot studi bmn
develop quotient appropri endpoint per fda bmn
kind durabl think need demonstr valrox offer
think fda deem annual growth veloc improv
approv endpoint without demonstr improv proportion
talk decis use pku gene therapi
strategi convert eu patient kuvan palynziq
statu dmd program
share under-perform nasdaq biotechnolog index
compar respect
share ralli peak dip level along
overal market perform lentiglobin present encourag
clinic ukptipd relapsed/refractori multipl myeloma r/r mm sickl cell diseas
scd eha meet respect investor sold stock news
choppi due gener eros small-cap valuat well intensifi
competit bcma space includ amgn bcma bite despit promis data
next-gener car-t therapi consist perform
lentiglobin case develop myelodysplast syndrom rais potenti safeti
concern lead dip share
exhibit price perform rel
lead gene therapi compani current two late-stag cell therapi
asset lentiglobin bcma car-t treatment hemoglobinopathi
r/r mm respect demonstr strong efficaci safeti
heavili pretreat mm patient current pivot develop partner
celg top-lin readout expect competit bcma space
intensifi believ remain leader signific opportun exist
earlier line date lentiglobin gener durabl target gene express
-thalassemia scd howev whether anti-sickl protein correl
improv clinic outcom scd yet known await clarif blue
registr strategi scd
focu file scd strategi
pivot karmma trial r/r mm expect read-out partner celg
plan file fda approv year primari endpoint overal respons
await data durabl all-com patient regardless bcma level seek
potenti acceler approv lentiglobin scd expand
trial explor correl multipl surrog endpoint clinic outcom
reduct incid vaso-occlus episod addit eu approv
lentiglobin thalassemia expect maintain neutral
reduc po base bcma competit unclear regulatori
path sickl cell diseas well conserv view lentiglobin eu launch
lentiglobin assum previous probabl approv beta-
thalassemia previous sickl cell anemia lenti-d ccald
assum previous likelihood approv base posit phase i/ii
proof-of-concept data assum unchang likelihood success
top-lin data karmma trial relapsed/refractori mm
potenti file fda relapsed/refractori mm
initi pivot trial sickl cell diseas
continu updat lentiglobin trial
-thalassemia sickl cell diseas
potenti approv lentiglobin thalassemia
question manag
think competit landscap bcma target therapi
light earli result well differ modal bite
expect durabl data regardless bcma level
upcom phase readout although primari endpoint orr
requir durabl data file fda approv expect durabl similar
high bcma expressor
expect durabl data condit
partner celg move forward registr studi
expect correl data hemoglobin clinic
outcom kind data warrant use surrog endpoint
patient expect transfus independ new
potenti approv lentiglobin thalassemia europ next year
plan roll launch start convers payer
one md case report month post lentiglobin infus could
provid detail case commun fda potenti
promis data program treatment scd
plan condit initi registr trial
compar approach express hemoglobin suppress
collabor go go hear
updat collabor
celg share ytd under-perform
biotechnolog index follow multipl setback late result major stock
pullback celg begin bang acquir impact biomedicin
up-front howev acquisit seen
compani me-too product rather late-stag innov product abl
fill revlimid revenu gap challeng regard ozanimod regulatori file
brought manag question result fair amount manag turnov
second-half year includ posit pipelin updat suggest
resurg celg pipelin prowess howev investor seem remain
sidelin watch progress step back name
exhibit celg price perform rel
revlimid celg biggest near-term growth driver increas market share
durat use triplet combin market uptak otezla continu impress
plaqu psoriasi well y/i growth multipl phase trial
underway revlimid pomalyst otezla potenti expand use given
long-term debt cash equival see celg
disciplin bd pursu believ pipelin progress pick
five nda expect revlimid concentr risk like mute
strength profit growth decreas revenu growth project
revlimid reduc po
focu pipelin growth beyond revlimid
import year gain investor confid show opportun
pipelin beyond revlimid expect launch five late-stag product
includ ozanimod ms fedratinib mf luspatercept md -thalassemia
mm dlbcl smooth execut regulatori file
approv necessari regain investor confid focu remain
continu leadership multipl myeloma mm strategi surround multipl
celmod becom clear next year base case includ gener revlimid
entrant us investor continu focu revlimid patent protect
potenti litigation/settl dr reddi
re-fil ozanimod ms
complet enrol phase north uc
file luspatercept mds/-thal revlimid/rituximab r/r nhl
pivot data dlbcl nda file
updat result
question manag
revlimid volum treatment durat us/ex-u way
close gap us eu treatment durat
commerci opportun follicular lymphoma revlimid
think differ vs r/r set relev
confid level around otezla franchis respect price
market dynam could guidanc drop overal market
continu show declin growth
studi requir re-fil ozanimod studi
could elabor strateg commerci plan ozanimod respect
initi neurolog sale franchis differenti gilenya
compet tecfidera earlier-lin multipl sclerosi ms
convers fda regard remov first-dos
monitor ozanimod perceiv
comment ip strategi potenti settl dr reddys/oth
second gener entrant impact estim guidanc
could see upsid patent expiri pomalyst due method
use patent pomalyst expir current model
differenti term efficaci
toler may expect data asset
multipl myeloma patient subgroup may respond better one
celmod anoth
could see trial head-to-head revlimid
commit bcma-target therapi plan posit
car-t bi-specif asset treatment paradigm
phase compar triplet regimen dpd dvd ird
request regulatori agenc
color time ozanimod ulcer coliti data
enrol slower expect
intern expect abraxan io protect
gener entrant
see updat juno program solid tumor
see differenti juno technolog compar
cell therapeut
pay donut hole part financi
impact
under-perform nasdaq biotechnolog index ytd
perform strong high reach march
investor excit first-in-human data wholly-own probodi
platform includ howev investor enthusiasm
temper lack conclus data american societi clinic oncolog
expect lead sell follow high data show
efficaci safeti similar monoclon antibodi lack clear
differenti due asset select lack present
medic confer rais concern see probodi platform
differenti decreas penetr estim indic entrench
inhibitor reduc po maintain buy rate note
matur result wholly-own partner asset drive news flow
exhibit price perform rel
clinic stage compani matur respons data anticip
believ partner bring asset clinic
provid proof-of-concept data increas awar excit around name
ensu ctmx lead asset target valid target multipl tumor
type opportun becom backbon cancer therapi see
substanti upsid probodi technolog given use monoclon antibodi
cancer therapi achiev consider success uptak recent year
improv safeti would well receiv ctmx strong cash posit
put good posit drive develop five clinic probodi asset
focu matur data wholly-own asset
updat data probodi probodi
drug conjug expect throughout first clinic data left investor
unenthus data higher dose larger diseas cohort allow
interpret data look toward intratumor activ unmask probodi
percent receptor occup hint intend probodi mechan action given
broad healthi tissu express target watch advers
safeti signal phase proclaim studi also watch partner
probodi data disclosur anticip
